NanoBUP (buprenorphine/naloxone) / National Resilience - LARVOL DELTA

TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) - "TCR2 to present an interim update from the Phase 1 portion of the TC-110 Phase 1/2 clinical trial for patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia in the second half of 2021. TCR2 plans to file an IND for TC-510, the first enhanced TRuC-T cell (targeting mesothelin with a PD-1:CD28 switch), in the second half of 2021."

IND • P1 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology